Nov 07, 2024 / 10:00PM GMT
Operator
Good afternoon, ladies and gentlemen and welcome to the Vistagen Therapeutics fiscal year 2025, second quarter corporate update conference call. (Operator Instructions)
I would now like to turn the call over to Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Please go ahead.
Mark Mcpartland - Vistagen Therapeutics Inc - Senior Vice President, Investor Relations
Thank you operator. Good afternoon, everyone and welcome to Vistagen fiscal year 2025 second quarter, corporate update conference call and webcast. Earlier this afternoon, we filed our quarterly report with the securities exchange commission on the SEC form 10-Q for second quarter that ended September 30, 2024 and we also issued a press release providing an overview of our progress across our lead neuroscience programs.
We encourage you to review the release in our 10-Q which can be found in the investors section of our website. We will make forward-looking statements regarding our business during today's call based on our current expectations and information.
Q2 2025 Vistagen Therapeutics Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot